Evidence Summary on AstraZeneca COVID-19 vaccine as Second Booster/ Fourth Dose for the prevention of COVID-19
HTAC RECOMMENDATION ON THE PNF INCLUSION OF abiraterone acetate in combination with prednisone and enzalutamide for individuals with metastatic castration-resistant prostate cancer
HTAC RECOMMENDATION ON THE PNF INCLUSION OF REMDESIVIR FOR ADULT PATIENTS WITH COVID-19 REQUIRING HOSPITALIZATION
HTAC Recommendation for the Inclusion of Zoledronic Acid for Individuals with Malignancy-Related Bone Disease in the Philippine National Formulary (PNF)
HTAC Guidance: Limited evidence of improved protection from 2nd booster dose among healthy individuals aged 18-49 years
HTAC Recommendation on the Second Booster of COVID-19 vaccines for the prevention of COVID-19 among individuals aged 50 years old and older and individuals with comorbidities aged 18 to 49 years old
